Biotechnology

Telix Pharmaceuticals

Telix Pharmaceuticals Issued Convertible Bonds

Telix Pharmaceuticals released FY2025 Q3 earnings on February 19 (EST), actual revenue USD 206.72 M (forecast USD 212.4 M), actual EPS USD -0.0083 (forecast USD -0.1309)

Telix Pharmaceuticals released FY2025 9 Months earnings on February 19, 2026 (EST), with actual revenue of USD 597.08 M and EPS of USD -0.0151

Telix Pharmaceuticals released FY2025 Q4 earnings on February 19 During-Market EST, actual revenue USD 0 (forecast USD 221.85 M), actual EPS USD 0 (forecast USD 0.0299)

Telix Pharmaceuticals released FY2025 earnings on February 19 During-Market (EST), actual revenue USD 803.79 M (forecast USD 824.16 M), actual EPS USD -0.0211 (forecast USD 0.0256)

Telix Pharmaceuticals to Release FY2025 Earnings on February 18 During-Market EST, Forecast Revenue USD 824.16 M, EPS USD 0.0253

Telix Pharmaceuticals Reports FY2025 Revenue of About $804 Million

Telix Pharmaceuticals Presents Radio-Pharmaceutical Portfolio and Precision Medicine Strategy

Telix Pharmaceuticals to release FY2025 Q4 earnings on January 19, 2026 Pre-Market EST, forecast revenue USD 221.33 M, EPS USD 0.0299

TD Cowen Analyst Reiterates Buy Rating on Telix Pharmaceuticals with a Price Target of 25 Australian Dollars

Telix Pharmaceuticals Pursues FDA Resubmission

RBC Capital gives Telix Pharmaceuticals a hold rating

Telix Pharmaceuticals Updates Trading Policy

Telix Pharmaceuticals Announces Clinical Collaboration with Varian for Prostate Cancer Radiotherapy

Analyst Shane Storey Maintains Buy Rating on Telix Pharmaceuticals

JPMorgan Discloses Holding in Telix Pharmaceuticals Ltd.

Medpace and Telix Partner on Phase III Clinical Trial of 177Lu-TLX250

Telix Pharmaceuticals Faces SEC subpoena over Prostate Cancer Drug Disclosures

Hester Recommends Attention to Telix Pharmaceuticals and Other Healthcare Stocks

Telix Pharmaceuticals Launches Phase I Clinical Trial for Radiopharmaceutical TLX090 for Bone Metastasis Pain

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Telix Pharmaceuticals has completed patient enrolment for the IPAX-2 study of TLX101-Tx in newly diagnosed glioblastoma, achieving maximum dosing without dose-limiting toxicities. This Phase 1 study evaluates TLX101-Tx's safety alongside standard treatments. The company is also conducting the pivotal IPAX BrIGHT trial for recurrent glioblastoma. TLX101-Tx targets LAT1, over-expressed in glioblastoma, and has received orphan drug designation in the U.S. and Europe.

StockTitan

Telix Pharmaceuticals Ltd.

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing | TLX Stock News

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | TLX Stock News

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | TLX Stock News

Telix Pharmaceuticals (ASX:TLX) has gained attention following the FDA's acceptance of its resubmitted New Drug Application for Pixclara and reaffirmation of its FY2026 revenue guidance. The stock has seen a 59.91% return over 90 days but is down 43.19% over the past year. Analysts suggest a fair value of A$18.00, indicating the stock may be undervalued at A$14.52. The company's strategy includes vertical integration through acquisitions, which could enhance margins and supply reliability. However, future growth depends on clinical trial outcomes and market conditions.

Simplywall

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones

Telix Pharmaceuticals Limited presented dosimetry data from the Phase 2 OPTIMAL-PSMA trial for TLX597-Tx, a radioligand therapy for metastatic castration-resistant prostate cancer. The trial, involving 120 men, showed low uptake in salivary glands and kidneys, supporting a dose-intensification regimen to enhance treatment effectiveness and reduce side effects. The company is also launching a Phase 2 study for androgen pathway-sensitive prostate cancer and advancing TLX591-Tx in a Phase 3 trial. TLX stock closed at $11.00, up 5.47%, and is trading at $11.20 in the overnight market, up 1.82%.

nasdaq

Nasdaq

Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment

TLX101-Px (Pixlumi®) MAA Accepted in Europe | TLX Stock News

TLX101-Px (Pixlumi®) MAA Accepted in Europe | TLX Stock News

Telix Pharmaceuticals(TLX.US)

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing | TLX Stock News

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | TLX Stock News

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones

Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment

TLX101-Px (Pixlumi®) MAA Accepted in Europe | TLX Stock News